STOCK TITAN

Polypid Ltd. Stock Price, News & Analysis

PYPD Nasdaq

Welcome to our dedicated page for Polypid Ltd. news (Ticker: PYPD), a resource for investors and traders seeking the latest updates and insights on Polypid Ltd. stock.

PolyPid Ltd (PYPD) is a clinical-stage biopharmaceutical company advancing surgical care through its proprietary PLEX drug delivery platform. This page provides investors and industry professionals with timely updates on clinical developments, regulatory milestones, and corporate news directly impacting PolyPid's growth trajectory.

Access consolidated information on Phase 3 trial results for D-PLEX100 in surgical infection prevention, technology licensing agreements, and strategic pipeline expansions. Our news collection serves as a neutral, fact-based resource for tracking PolyPid's progress in transforming localized drug delivery.

Key updates include clinical trial data disclosures, FDA/EMA regulatory communications, and partnership announcements related to PLEX applications. Bookmark this page to monitor PolyPid's advancements in prolonged-release therapeutics and their potential impact on surgical outcomes and oncology care.

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) has announced that the European Medicines Agency (EMA) confirmed D-PLEX100 is eligible for a centralized Marketing Authorization Application (MAA). This allows D-PLEX100 to be marketed across all EU member states upon approval. The centralized procedure highlights D-PLEX100 as a potential new option for preventing post-abdominal surgical site infections (SSIs). The company is also evaluating data from its recent Phase 3 SHIELD I trial and plans discussions with regulatory authorities in early 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.67%
Tags
none
-
Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) announced positive clinical data from a Phase 2 study of D-PLEX100, aimed at preventing surgical site infections (SSIs) in abdominal surgery. The study showed a 64% relative risk reduction in infection rates, with 8% in the D-PLEX100 group compared to 22% in the control group. Following the results, the company plans to meet with FDA and EU regulatory authorities in Q1 2023 to discuss next steps for D-PLEX100 as it transitions into Phase 3 trials. The product has already received Breakthrough Therapy Designation from the FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
-
Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) announced that Phase 2 clinical data for D-PLEX100 will be presented at the European Society for Coloproctology Scientific Conference from September 21-23, 2022, in Dublin, Ireland. The lead candidate D-PLEX100 is designed to prevent surgical site infections through a controlled release of doxycycline for 30 days. The presentation, by Dr. Anthony J. Senagore, aims to highlight the product's potential in improving surgical outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
58.33%
Tags
Rhea-AI Summary

PolyPid Ltd. announced top-line results from its SHIELD I Phase 3 study of D-PLEX100 for preventing surgical site infections (SSIs) in abdominal surgery. The trial did not achieve its primary endpoint of reducing SSIs and mortality overall, with a 23% reduction in SSIs (p=0.1520). However, a subgroup analysis of patients with incision lengths over 20 cm showed a significant 54% reduction in SSIs (p<0.0032). The independent Data Safety Monitoring Board found no safety concerns. PolyPid plans to discuss results with the FDA and further assess next steps.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-73.47%
Tags
-
Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) announced the presentation of Phase 2 clinical and animal study data for D-PLEX100 at the 2022 Military Health System Research Symposium from September 12-15, 2022. The podium presentation will address D-PLEX100's efficacy in reducing surgical site infection rates and drug-resistant bacteria in surgical trauma injuries. This presentation will be led by Noam Emanuel, PhD, Co-Founder and Chief Scientific Officer. D-PLEX100 is currently in Phase 3 trials aimed at preventing surgical site infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
none
-
Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) announced an exclusive licensing agreement with ADVANZ PHARMA for D-PLEX100, targeting over $110 million in upfront and milestone payments, plus potential royalties. The agreement aims to commercialize D-PLEX100 for preventing surgical site infections in Europe. The independent Data Safety Monitoring Board recommended concluding the Phase 3 SHIELD I trial after 950 patient enrollments. Top-line results are expected by the end of Q3 2022, with potential NDA submission in 2023. For Q2 2022, the company reported a loss of $11.8 million, increasing R&D expenses to $8.4 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) has partnered with ADVANZ PHARMA to commercialize D-PLEX100 in Europe for preventing surgical site infections (SSIs) in abdominal and cardiac surgeries. The agreement offers PolyPid an upfront payment of $2.6 million and a total of up to $23.5 million in developmental milestones. Additionally, PolyPid anticipates up to $89 million in sales-related milestones and royalties on net sales. This collaboration leverages ADVANZ PHARMA's expertise and resources to enhance access to this vital therapy, pending approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.83%
Tags
none
-
Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) announced the upcoming release of its Q2 2022 financial results and operational highlights on August 10, 2022, before U.S. market open. A conference call is set for 8:30 a.m. Eastern Time to discuss the results and business updates. PolyPid is a late-stage biopharma company focused on improving surgical outcomes, leveraging its PLEX technology for drug delivery. Their lead candidate, D-PLEX100, is in Phase 3 trials targeting surgical site infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.97%
Tags
conferences earnings
-
Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) announced that Phase 2 clinical data for its lead product candidate D-PLEX100 will be presented at the Midwest Surgical Association 2022 Annual Meeting on August 8, 2022. This podium presentation, titled Reduction in Surgical Site Infections by Localized Administration with D-PLEX100 in Patients with Multiple Risk Factors Undergoing Colorectal Surgery, will be given by Senior Medical Director Dr. Anthony J. Senagore. D-PLEX100 aims to prevent infections post-abdominal surgery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.09%
Tags
Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) has announced the appointment of Dikla Czaczkes Akselbrad as the new CEO, effective July 1, 2022. Formerly the Executive Vice President and CFO, Akselbrad brings over 20 years of experience in life sciences. Her leadership is expected to be vital as the company prepares for a potential New Drug Application submission and the commercialization of D-PLEX100. The company recently completed its SHIELD I Phase 3 study, with top-line results anticipated by the end of the current quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.29%
Tags
none

FAQ

What is the current stock price of Polypid Ltd. (PYPD)?

The current stock price of Polypid Ltd. (PYPD) is $3.5 as of July 16, 2025.

What is the market cap of Polypid Ltd. (PYPD)?

The market cap of Polypid Ltd. (PYPD) is approximately 35.0M.
Polypid Ltd.

Nasdaq:PYPD

PYPD Rankings

PYPD Stock Data

34.95M
7.07M
25.09%
53.36%
0.09%
Biotechnology
Healthcare
Link
Israel
Petah Tikva